Latest News for: neurotrophic

Edit

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis (Form 8-K) (Krystal Biotech Inc)

Public Technologies 09 Jul 2025
) Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis ... study evaluating KB801 for the treatment of neurotrophic keratitis (NK).
Edit

Neurotrophic Keratitis Treatment Market Report 2025: $22.6 Bn Opportunities and Strategies to 2034 - Recombinant ...

Nasdaq Globe Newswire 03 Jun 2025
The neurotrophic keratitis treatment market will expand from $1.07 billion in 2024 to $22.6 billion in 2034, fueled by rising aging ...
  • 1

Article Search

tools
×
×
×
×